| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2009PLoSO...4.7670W |
| P356 | DOI | 10.1371/JOURNAL.PONE.0007670 |
| P932 | PMC publication ID | 2765613 |
| P698 | PubMed publication ID | 19888321 |
| P5875 | ResearchGate publication ID | 38066089 |
| P50 | author | Lance A. Liotta | Q74243861 |
| Claudio Belluco | Q42660720 | ||
| Antonella Ravaggi | Q50860765 | ||
| P2093 | author name string | Jennifer B Edwards | |
| Sergio Pecorelli | |||
| Emanuel F Petricoin | |||
| Mark M Ross | |||
| Weidong Zhou | |||
| Octavio A Quiñones | |||
| W Gregory Alvord | |||
| Ren-Ming Dai | |||
| Bih-Rong Wei | |||
| R Mark Simpson | |||
| Shelley B Hoover | |||
| Kevin D Woolard | |||
| John I Risinger | |||
| Paul K Goldsmith | |||
| Francesco Meani | |||
| Elio Campagnutta | |||
| Luca Martella | |||
| Elizabeth I Spehalski | |||
| P2860 | cites work | Cancer statistics, 2008 | Q27860585 |
| Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type | Q28139003 | ||
| The S100 family of EF-hand calcium-binding proteins: functions and pathology | Q28284255 | ||
| S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles | Q29620465 | ||
| Use of proteomic patterns in serum to identify ovarian cancer | Q30819686 | ||
| Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front | Q30989699 | ||
| Quantitative analysis of the low molecular weight serum proteome using 18O stable isotope labeling in a lung tumor xenograft mouse model | Q33217936 | ||
| Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance | Q33230560 | ||
| Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue | Q33247421 | ||
| The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? | Q33333319 | ||
| Altered {beta}-catenin accumulation in hepatocellular carcinomas of diethylnitrosamine-exposed rhesus macaques | Q33382038 | ||
| Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker | Q33427212 | ||
| Ovarian cancer: pathology, biology, and disease models | Q33807748 | ||
| Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer | Q34354775 | ||
| Cancer of the ovary | Q34375262 | ||
| Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis | Q35098091 | ||
| Status of Tumor Markers in Ovarian Cancer Screening | Q35125949 | ||
| Biomarkers of ovarian tumours | Q35948065 | ||
| S100A6 and CacyBP/SIP - two proteins discovered in ehrlich ascites tumor cells that are potentially involved in the degradation of beta-catenin. | Q36337330 | ||
| Determining confidence limits for drug potency in immunoassay | Q56892435 | ||
| Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma | Q68937474 | ||
| Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor | Q71039623 | ||
| Early-stage ovarian cancer: to treat or not to treat | Q78799253 | ||
| Expression of S100A2 and S100A6 in thyroid carcinomas | Q81670742 | ||
| Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry | Q36682379 | ||
| Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers | Q36855240 | ||
| Calcium, troponin, calmodulin, S100 proteins: from myocardial basics to new therapeutic strategies | Q36983008 | ||
| A mouse model repository for cancer biomarker discovery | Q37056695 | ||
| Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry | Q37394015 | ||
| Epithelial ovarian cancer: focus on genetics and animal models | Q37394549 | ||
| Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer | Q38289312 | ||
| Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent | Q38350940 | ||
| Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). | Q40141847 | ||
| Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice | Q40223413 | ||
| Characterization of an antibody that can detect the Kai1/CD82 murine metastasis suppressor | Q40337214 | ||
| The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. | Q40352989 | ||
| High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients | Q40434420 | ||
| Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human | Q40518302 | ||
| Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo | Q41861199 | ||
| Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma | Q42279613 | ||
| Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves | Q42596115 | ||
| Calcyclin as a marker of human epithelial cells and fibroblasts | Q43782820 | ||
| Albumin binding as a general strategy for improving the pharmacokinetics of proteins | Q44209151 | ||
| The blood peptidome: a higher dimension of information content for cancer biomarker discovery | Q44924621 | ||
| Proteomic global profiling for cancer biomarker discovery. | Q46110250 | ||
| A method for the selective isolation and enrichment of carrier protein-bound low-molecular weight proteins and peptides in the blood | Q47303706 | ||
| S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples. | Q53334864 | ||
| Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. | Q53360582 | ||
| Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. | Q53657596 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P4510 | describes a project that uses | ACI-8 | Q54608406 |
| ACI-89 | Q54608411 | ||
| ImageQuant | Q112270642 | ||
| ACI-1 | Q54608376 | ||
| ACI-17 | Q54608382 | ||
| ACI-23 | Q54608388 | ||
| ACI-27 | Q54608390 | ||
| ACI-35 | Q54608392 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| cell line | Q21014462 | ||
| P304 | page(s) | e7670 | |
| P577 | publication date | 2009-10-30 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients | |
| P478 | volume | 4 |
| Q35736782 | A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer |
| Q38194543 | Application of proteomics in the study of rodent models of cancer. |
| Q34819898 | Capacity for resolution of Ras-MAPK-initiated early pathogenic myocardial hypertrophy modeled in mice |
| Q37090146 | Cell proliferation and oxidative stress pathways are modified in fibroblasts from Sturge-Weber syndrome patients |
| Q38767850 | Characterization of ovarian cancer cell lines as in vivo models for preclinical studies |
| Q34992944 | Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: evidence from an experimental study |
| Q64269509 | Identification of diagnostic upper gastrointestinal cancer tissue type‑specific urinary biomarkers |
| Q37607036 | In-depth LC-MS/MS analysis of the chicken ovarian cancer proteome reveals conserved and novel differentially regulated proteins in humans |
| Q37732704 | Molecular imaging and targeted therapies |
| Q60044321 | Prognostic values of S100 family members in ovarian cancer patients |
| Q52970611 | Programmed cell death 6 interacting protein (PDCD6IP) and Rabenosyn-5 (ZFYVE20) are potential urinary biomarkers for upper gastrointestinal cancer. |
| Q37187957 | Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer |
| Q43736159 | Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome lea |
| Q44994835 | Proteomic profiling of H-Ras-G12V induced hypertrophic cardiomyopathy in transgenic mice using comparative LC-MS analysis of thin fresh-frozen tissue sections |
| Q30425624 | Proteomic profiling of a mouse model for ovarian granulosa cell tumor identifies VCP as a highly sensitive serum tumor marker in several human cancers |
| Q33891197 | Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead |
| Q28082632 | Proteomics of ovarian cancer: functional insights and clinical applications |
| Q37650123 | S100 protein family in human cancer |
| Q39247295 | S100A6 protein: functional roles |
| Q92358099 | Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells |
| Q36019903 | The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity |
Search more.